Don't reduce chemotherapy dose for obese women with ER-negative breast Ca

Article

It seems obese breast cancer patients are frequently underdosed when it comes to chemotherapy.

It seems obese breast cancer patients are frequently underdosed when it comes to chemotherapy.

Researchers reviewed data from four randomized trials of the International Breast Cancer Study Group assessing the use of adjuvant classical chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil in premenopausal women with node-positive breast cancer.

They found that 39% of obese women received less than 85% of the chemotherapy dose specified by the protocol versus 16% of women with normal or intermediate body mass index. While this didn't significantly compromise outcome in the women with estrogen-receptor (ER)–positive disease, reducing the dose of chemotherapy was associated with a significantly worse outcome in the obese women with ER-negative cancer in terms of disease-free survival (total population hazards ratio ≥ 85% vs. <85%, 0.68, 95% CI; 0.54–0.86, P=0.0013) and overall survival (0.72, 0.56-0.94, P=0.0142).

Recent Videos
First US national HPV conference highlights advances in cancer prevention | Image Credit: uchealth.com.
Mitchell Creinin, MD, reports estetrol pill eases menstrual symptoms | Image Credit: health.ucdavis.edu
1 expert is featured in this series.
Susanna Mitro, PhD, reveals ethnic disparities in uterine fibroid diagnosis | Image Credit: divisionofresearch.kaiserpermanente.org.
Shayna Mancuso, DO, highlights the real impact of menopause | Image Credit: linkedin.com.
Jihong Liu, ScD, explains how to improve perinatal outcomes in COVID patients | Image Credit: sc.edu.
1 expert is featured in this series.
Jihong Liu, ScD, highlights adverse perinatal outcomes linked to the COVID pandemic | Image Credit: sc.edu.
Experts highlight infant health benefits from minor diet changes in pregnancy | Image Credit: ohsu.edu.
Connie Stark, RNC, PNC, provides fertility preservation insights for endometriosis patients | Image Credit: linkedin.com.
Related Content
© 2025 MJH Life Sciences

All rights reserved.